Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 81

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Hemostatic agents for prehospital hemorrhage control: a narrative review

Peng, Henry T. · 2020 · Military Medical Research

Abstract

Hemorrhage is the leading cause of preventable death in combat trauma and the secondary cause of death in civilian trauma. A significant number of deaths due to hemorrhage occur before and in the first hour after hospital arrival. A literature search was performed through PubMed, Scopus, and Institute of Scientific Information databases for English language articles using terms relating to hemostatic agents, prehospital, battlefield or combat dressings, and prehospital hemostatic resuscitation, followed by cross-reference searching. Abstracts were screened to determine relevance and whether appropriate further review of the original articles was warranted. Based on these findings, this paper provides a review of a variety of hemostatic agents ranging from clinically approved products for human use to newly developed concepts with great potential for use in prehospital settings. These hemostatic agents can be administered either systemically or locally to stop bleeding through different mechanisms of action. Comparisons of current hemostatic products and further directions for prehospital hemorrhage control are also discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40779-020-00241-z

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 222

  1. Stannard A, Morrison JJ, Scott DJ, Ivatury RA, Ross JD, Rasmussen TE. The epidemiology of noncompressible torso hemorrhage in the wars in Iraq and Afghanistan. J Trauma Acute Care Surg. 2013;74(3):830–4. · doi:10.1097/ta.0b013e31827a3704
  2. Eastridge BJ, Hardin M, Cantrell J, Oetjen-Gerdes L, Zubko T, Mallak C, et al. Died of wounds on the battlefield: causation and implications for improving combat casualty care. J Trauma. 2011;71(1):S4–8. · DOI · Paper page
  3. Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, et al. Death on the battlefield (2001–2011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012;73(6):S431–7. · DOI · Paper page
  4. Norton R, Kobusingye O. Injuries. N Engl J Med. 2013;368(18):1723–30. · DOI · Paper page
  5. National Academies of Sciences Engineering and Medicine. A national trauma care system: integrating military and civilian trauma systems to achieve zero preventable deaths after injury. Washington, DC: The National Academies Press; 2016. p. 530.
  6. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma Acute Care Surg. 2008;65(4):748–54. · DOI · Paper page
  7. Davenport RA, Brohi K. Cause of trauma-induced coagulopathy. Curr Opin Anesthesiol. 2015;29(2):212–9. · DOI
  8. Stephens CT, Gumbert S, Holcomb JB. Trauma-associated bleeding: management of massive transfusion. Curr Opin Anesthesiol. 2016;29(2):250–5. · doi:10.1097/aco.0000000000000306
  9. Martin M, Oh J, Currier H, Tai N, Beekley A, Eckert M, et al. An analysis of in-hospital deaths at a modern combat support hospital. J Trauma. 2009;66(4):S51–61. · DOI
  10. Pidcoke HF, Spinella PC. RDCR symposium fifth-year anniversary edition: global prehospital care rooted in a history of military innovation. Transfusion. 2016;56(Suppl 2):S107–9. · doi:10.1111/trf.13606
  11. Chang R, Eastridge BJ, Holcomb JB. Remote damage control resuscitation in austere environments. Wilderness Environ Med. 2017;28(2):S124–34. · doi:10.1016/j.wem.2017.02.002
  12. MacGoey P, Lamb CM, Navarro AP, Brooks AJ. Damage control: the modern paradigm. Trauma. 2016;18(3):165–77. · DOI
  13. Smith IM, James RH, Dretzke J, Midwinter MJ. Pre-hospital blood product resuscitation for trauma: a systematic review. Shock. 2016;46(1):3–16. · doi:10.1097/shk.0000000000000569
  14. Shand S, Curtis K, Dinh M, Burns B. What is the impact of prehospital blood product administration for patients with catastrophic haemorrhage: an integrative review. Injury. 2019;50(2):226–34. · doi:10.1016/j.injury.2018.11.049
  15. Rijnhout TWH, Wever KE, Marinus R, Hoogerwerf N, Geeraedts LMG Jr, Tan E. Is prehospital blood transfusion effective and safe in haemorrhagic trauma patients? A systematic review and meta-analysis. Injury. 2019;50(5):1017–27. · DOI
  16. Fenger-Eriksen C, Fries D, David J-S, Bouzat P, Lance MD, Grottke O, et al. Pre-hospital plasma transfusion: a valuable coagulation support or an expensive fluid therapy? Crit Care. 2019;23(1):238. · doi:10.1186/s13054-019-2524-4
  17. van Oostendorp SE, Tan ECTH, Geeraedts LMG. Prehospital control of life-threatening truncal and junctional haemorrhage is the ultimate challenge in optimizing trauma care; a review of treatment options and their applicability in the civilian trauma setting. Scand J Trauma Res Emerg Med. 2016;24(1):1–13. · DOI
  18. Rappold JF, Bochicchio GV. Surgical adjuncts to noncompressible torso hemorrhage as tools for patient blood management. Transfusion. 2016;56(Suppl 2):203–7. · doi:10.1111/trf.13585
  19. Smith AH, Laird C, Porter K, Bloch M. Haemostatic dressings in prehospital care. J Emerg Med. 2013;30(10):784–9. · DOI
  20. Sigal A, Martin A, Ong A. Availability and use of hemostatic agents in prehospital trauma patients in Pennsylvania translation from the military to the civilian setting. Open Access Emerg Med. 2017;9:47–52. · DOI
  21. Neuffer MC, McDivitt J, Rose D, King K, Cloonan CC, Vayer JS. Hemostatic dressings for the first responder: a review. Mil Med. 2004;169(9):716–20. · DOI
  22. Pusateri AE, Delgado AV, Dick EJ Jr, Martinez RS, Holcomb JB, Ryan KL. Application of a granular mineral-based hemostatic agent (QuikClot) to reduce blood loss after grade V liver injury in swine. J Trauma. 2004;57(3):555–62. · doi:10.1097/01.ta.0000136155.97758.cd
  23. Peng T. Biomaterials for hemorrhage control. Trends Biomater Artif Organs. 2010;24(1):27–68.
  24. Baylis JR, Chan KYT, Kastrup CJ. Halting hemorrhage with self-propelling particles and local drug delivery. Thromb Res. 2016;141(Suppl 2):36–9. · DOI
  25. Chaturvedi A, Dowling MB, Gustin JP, Scalea TM, Raghavan SR, Pasley JD, et al. Hydrophobically modified chitosan gauze: a novel topical hemostat. J Surg Res. 2017;207:45–52. · DOI
  26. Peng H, Shek P. Development of in situ-forming hydrogels for hemorrhage control. J Mater Sci Mater Med. 2009;20(8):1753–62. · DOI
  27. Peng HT, Blostein MD, Shek PN. Experimental optimization of an in situ forming hydrogel for hemorrhage control. J Biomed Mater Res B. 2009;89(1):199–209. · DOI
  28. Rago AP, Duggan MJ, Beagle J, Peev MP, Marini J, Hwabejire JO, et al. Self-expanding foam for prehospital treatment of intra-abdominal hemorrhage: 28-day survival and safety. J Trauma Acute Care Surg. 2014;77(3):S127–33. · doi:10.1097/ta.0000000000000380
  29. Otrocka-Domagała I, Jastrzębski P, Adamiak Z, Paździor-Czapula K, Gesek M, Mikiewicz M, et al. Safety of the long-term application of QuikClot combat gauze, ChitoGauze PRO and Celox gauze in a femoral artery injury model in swine–the preliminary study. Pol J Vet Sci. 2016;19(2):337–43. · doi:10.1515/pjvs-2016-0041
  30. Kheirabadi BS, Mace JE, Terrazas IB, Fedyk CG, Estep JS, Dubick MA, et al. Safety evaluation of new hemostatic agents, smectite granules, and kaolin-coated gauze in a vascular injury wound model in swine. J Trauma Acute Care Surg. 2010;68(2):269–78. · doi:10.1097/ta.0b013e3181c97ef1
  31. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. · DOI · Paper page
  32. Maegele M. Coagulation factor concentrate-based therapy for remote damage control resuscitation (RDCR): a reasonable alternative? Transfusion. 2016;56(Suppl 2):157–65. · doi:10.1111/trf.13526
  33. Matsushima K, Benjamin E, Demetriades D. Prothrombin complex concentrate in trauma patients. Am J Surg. 2015;209(2):413–7. · doi:10.1016/j.amjsurg.2014.08.019
  34. Nascimento B, Callum J, Tien H, Peng H, Rizoli S, Karanicolas P, et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. Br J Anaesth. 2016;117(6):775–82. · DOI
  35. Sanders S, Tien H, Callum J, Nascimento B, Peng H, Funk C, et al. Fibrinogen concentrate in the special operations forces environment. Mil Med. 2018;183(1–2):e45–50. · doi:10.1093/milmed/usx057
  36. Pusateri AE, Given MB, Schreiber MA, Spinella PC, Pati S, Kozar RA, et al. Dried plasma: state of the science and recent developments. Transfusion. 2016;56(Suppl 2):128–39. · DOI
  37. Shlaifer A, Siman-Tov M, Radomislensky I, Peleg K, Klein Y, Glassberg E, et al. The impact of pre pospital administration of freeze dried plasma on casualty outcome. J Trauma Acute Care Surg. 2018;86(1):108–15. · DOI
  38. Heier HE, Badloe J, Bohonek M, Cap A, Doughty H, Korsak J, et al. Use of Tranexamic acid in bleeding combat casualties. Mil Med. 2015;180(8):844–6. · doi:10.7205/milmed-d-14-00592
  39. Ausset S, Glassberg E, Nadler R, Sunde G, Cap AP, Hoffmann C, et al. Tranexamic acid as part of remote damage-control resuscitation in the prehospital setting: a critical appraisal of the medical literature and available alternatives. J Trauma Acute Care Surg. 2015;78(6):S70–5. · DOI
  40. El-Menyar A, Sathian B, Asim M, Latifi R, Al-Thani H. Efficacy of prehospital administration of tranexamic acid in trauma patients: a meta-analysis of the randomized controlled trials. Am J Emerg Med. 2018;36(6):1079–87. · DOI
  41. Huebner BR, Dorlac WC, Cribari C. Tranexamic acid use in prehospital uncontrolled hemorrhage. Wilderness Environ Med. 2017;28(2):S50–60. · doi:10.1016/j.wem.2016.12.006
  42. Fitzpatrick GM, Cliff R, Tandon N. Thrombosomes: a platelet-derived hemostatic agent for control of noncompressible hemorrhage. Transfusion. 2013;53(Suppl 1):100S–6. · DOI
  43. Macko AR, Crossland RF, Cap AP, Fryer DM, Mitchell TA, Pusateri AE, et al. Control of severe intra-abdominal hemorrhage with an infusible platelet-derived hemostatic agent in a nonhuman primate (rhesus macaque) model. J Trauma Acute Care Surg. 2016;80(4):617–24. · doi:10.1097/ta.0000000000000964
  44. Hawksworth JS, Elster EA, Fryer D, Sheppard F, Morthole V, Krishnamurthy G, et al. Evaluation of lyophilized platelets as an infusible hemostatic agent in experimental non-compressible hemorrhage in swine. J Thromb Haemost. 2009;7(10):1663–71. · doi:10.1111/j.1538-7836.2009.03562.x
  45. Bertram JP, Williams CA, Robinson R, Segal SS, Flynn NT, Lavik EB. Synthetic platelets: nanotechnology to halt bleeding. Sci Transl Med. 2009;1(11):11ra22. · DOI · Paper page
  46. Anselmo AC, Modery-Pawlowski CL, Menegatti S, Kumar S, Vogus DR, Tian LL, et al. Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano. 2014;8(11):11243–53. · DOI · Paper page
  47. Modery-Pawlowski CL, Tian LL, Pan V, McCrae KR, Mitragotri S, Sen GA. Approaches to synthetic platelet analogs. Biomaterials. 2013;34(2):526–41. · DOI
  48. Chan LW, White NJ, Pun SH. Synthetic strategies for engineering intravenous hemostats. Bioconjug Chem. 2015;26(7):1224–36. · DOI
  49. Chan LW, White NJ, Pun SH. A fibrin cross-linking polymer enhances clot formation similar to factor concentrates and tranexamic acid in an in vitro model of coagulopathy. ACS Biomater Sci Eng. 2016;2(3):403–8. · DOI
  50. Lamm RJ, Lim EB, Weigandt KM, Pozzo LD, White NJ, Pun SH. Peptide valency plays an important role in the activity of a synthetic fibrin-crosslinking polymer. Biomaterials. 2017;132:96–104. · doi:10.1016/j.biomaterials.2017.04.002
  51. Bennett BL, Littlejohn LF, Kheirabadi BS, Butler FK, Kotwal RS, Dubick MA, et al. Management of external hemorrhage in tactical combat casualty care: chitosan-based hemostatic gauze dressings. TCCC guidelines change 13-05. J Spec Oper Med. 2014;14(3):12–29. · DOI
  52. Bennett BL. Bleeding control using hemostatic dressings: lessons learned. Wilderness Environ Med. 2017;28(2):S39–49. · DOI
  53. Boulton AJ, Lewis CT, Naumann DN, Midwinter MJ. Prehospital haemostatic dressings for trauma: a systematic review. J Emerg Med. 2018;35(7):449–57. · DOI
  54. Sims K, Montgomery HR, Dituro P, Kheirabadi BS, Butler FK. Management of external hemorrhage in tactical combat casualty care: the adjunctive use of XStat™ compressed hemostatic sponges: TCCC guidelines change 15-03. J Spec Oper Med. 2016;16(1):19–28. · doi:10.55460/6cem-36iy
  55. Chang JC, Holloway BC, Zamisch M, Hepburn MJ, Ling GS. ResQFoam for the treatment of non-compressible hemorrhage on the front line. Mil Med. 2015;180(9):932–3. · doi:10.7205/milmed-d-15-00049
  56. Holcomb J, Nunez T. Damage control resuscitation. In: Martin M, Beekley A, editors. Front Line Surgery: Springer New York; 2011. p 47–58.
  57. Klages M, Zacharowski K, Weber CF. Coagulation management in trauma-associated coagulopathy: allogenic blood products versus coagulation factor concentrates in trauma care. Curr Opin Anesthesiol. 2016;29(2):245–9. · DOI
  58. Sperry JL, Guyette FX, Brown JB, Yazer MH, Triulzi DJ, Early-Young BJ, et al. Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. N Engl J Med. 2018;379(4):315–26. · DOI · Paper page
  59. Moore HB, Moore EE, Chapman MP, McVaney K, Bryskiewicz G, Blechar R, et al. Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial. Lancet. 2018;392(10144):283–91. · doi:10.1016/s0140-6736(18)31553-8
  60. Glassberg E, Nadler R, Gendler S, Abramovich A, Spinella PC, Gerhardt RT, et al. Freeze-dried plasma at the point of injury: from concept to doctrine. Shock. 2013;40(6):444–50. · doi:10.1097/shk.0000000000000047
  61. Aubron C, Reade MC, Fraser JF, Cooper DJ. Efficacy and safety of fibrinogen concentrate in trauma patients—a systematic review. J Crit Care. 2014;29(3):471 e11–7.
  62. Curry NS, Davenport R. Transfusion strategies for major haemorrhage in trauma. Br J Haematol. 2019;184(4):508–23. · DOI
  63. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract. 2008;62(10):1614–22. · doi:10.1111/j.1742-1241.2008.01859.x
  64. Grottke O, Levy JH. Prothrombin complex concentrates in trauma and perioperative bleeding. Anesthesiology. 2015;122(4):923–31. · DOI
  65. Peralta MR, Chowdary P. The use of new procoagulants in blunt and penetrating trauma. Curr Opin Anesthesiol. 2019;32(2):200–5. · doi:10.1097/aco.0000000000000696
  66. Buckley L, Gonzales R. Challenges to producing novel therapies - dried plasma for use in trauma and critical care. Transfusion. 2019;59(Suppl 1):837–45. · doi:10.1111/trf.14985
  67. Shlaifer A, Siman-Tov M, Radomislensky I, Peleg K, Shina A, Baruch EN, et al. Prehospital administration of freeze-dried plasma, is it the solution for trauma casualties? J Trauma Acute Care Surg. 2017;83(4):675–82. · doi:10.1097/ta.0000000000001569
  68. Sunde GA, Vikenes B, Strandenes G, Flo K-C, Hervig TA, Kristoffersen EK, et al. Freeze dried plasma and fresh red blood cells for civilian prehospital hemorrhagic shock resuscitation. J Trauma Acute Care Surg. 2015;78(6):S26–30. · doi:10.1097/ta.0000000000000633
  69. Oakeshott JE, Griggs JE, Wareham GM, Lyon RM. Feasibility of prehospital freeze-dried plasma administration in a UK helicopter emergency medical service. Eur J Emerg Med. 2019;26(5):373–8. · doi:10.1097/mej.0000000000000585
  70. Garrigue D, Godier A, Glacet A, Labreuche J, Kipnis E, Paris C, et al. French lyophilized plasma versus fresh frozen plasma for the initial management of trauma induced coagulopathy: a randomized open-label trial. J Thromb Haemost. 2017;16(3):481–9. · DOI
  71. Nguyen C, Bordes J, Cungi P-J, Esnault P, Cardinale M, Mathais Q, et al. Use of French lyophilized plasma transfusion in severe trauma patients is associated with an early plasma transfusion and early transfusion ratio improvement. J Trauma Acute Care Surg. 2018;84(5):780–5. · doi:10.1097/ta.0000000000001801
  72. Rottenstreich M, Malka I, Glassberg E, Schwartz O, Tarif B. Pre-hospital intra-osseous freeze dried plasma transfusion: a case report. Disaster Mil Med. 2015;1:8. · doi:10.1186/2054-314x-1-8
  73. Sailliol A, Martinaud C, Cap AP, Civadier C, Clavier B, Deshayes AV, et al. The evolving role of lyophilized plasma in remote damage control resuscitation in the French armed forces health service. Transfusion. 2013;53(Suppl 1):65S–71. · doi:10.1111/trf.12038
  74. Martinaud C, Ausset S, Deshayes AV, Cauet A, Demazeau N, Sailliol A. Use of freeze-dried plasma in French intensive care unit in Afghanistan. J Trauma Acute Care Surg. 2011;71(6):1761–5. · doi:10.1097/ta.0b013e31822f1285
  75. Pusateri AE, Given MB, Macdonald VW, Homer MJ. Comprehensive US government program for dried plasma development. Transfusion. 2016;56(Suppl 1):S16–23. · doi:10.1111/trf.13331
  76. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg. 2012;114(2):261–74. · DOI · Paper page
  77. Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth. 2010;105(2):116–21. · DOI · Paper page
  78. Rourke C, Curry N, Khan S, Taylor R, Raza I, Davenport R, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost. 2012;10(7):1342–51. · DOI · Paper page
  79. Kimura Y, Kimura S, Sumita S, Yamakage M. Predictors of hypofibrinogenemia in blunt trauma patients on admission. J Anesth. 2015;29(2):242–8. · doi:10.1007/s00540-014-1895-6
  80. Inaba K, Karamanos E, Lustenberger T, Schöchl H, Shulman I, Nelson J, et al. Impact of fibrinogen levels on outcomes after acute injury in patients requiring a massive transfusion. J Am Coll Surg. 2013;216(2):290–7. · doi:10.1016/j.jamcollsurg.2012.10.017
  81. Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10(1):23–7.
  82. Schulz PM, Gehringer W, Nöhring S, Müller S, Schmidt T, Kekeiss-Schertler S, et al. Biochemical characterization, stability, and pathogen safety of a new fibrinogen concentrate (fibryga®). Biologicals. 2018;52(1):72–7. · doi:10.1016/j.biologicals.2017.12.003
  83. Haas T, Cushing MM, Asmis LM. Comparison of the efficacy of two human fibrinogen concentrates to treat dilutional coagulopathy in vitro. Scand J Clin Lab Invest. 2018;78(3):230–5. · doi:10.1080/00365513.2018.1437645
  84. Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, et al. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. J Thromb Haemost. 2018;16(2):253–61. · doi:10.1111/jth.13923
  85. Djambas Khayat C, El Khorassani M, Lambert T, Gay V, Barthez-Toullec M, Lamazure J, et al. Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency. J Thromb Haemost. 2019;17(4):635–44. · doi:10.1111/jth.14392
  86. González-Guerrero C, Lozano-Andreu T, Roch-Santed M, Rivera-Sánchez L, Brandariz-Núñez D, Pastó-Cardona L, et al. Evaluation of the efficiency under current use of human fibrinogen concentrate in trauma patients with life-threatening hemorrhagic disorders. Blood Coagul Fibrinolysis. 2017;28(1):66–71. · doi:10.1097/mbc.0000000000000543
  87. Ozier Y, Hunt BJ. Fibrinogen concentrate for management of bleeding: against indiscriminate use. J Thromb Haemost. 2011;9(1):6–8. · doi:10.1111/j.1538-7836.2010.04083.x
  88. Kozek-Langenecker S, Fries D, Spahn DR, Zacharowski K. Fibrinogen concentrate: clinical reality and cautious Cochrane recommendation. Br J Anaesth. 2014;112(5):784–7. · DOI
  89. Bolliger D, Tanaka KA. Fibrinogen—is it a universal haemostatic agent? Br J Anaesth. 2016;117(5):548–50. · doi:10.1093/bja/aew332
  90. Maegele M, Zinser M, Schlimp C, Schöchl H, Fries D. Injectable hemostatic adjuncts in trauma: fibrinogen and the FIinTIC study. J Trauma Acute Care Surg. 2015;78(6):S76–82. · doi:10.1097/ta.0000000000000632
  91. Steinmetz J, Sørensen MA, Henriksen HH, Lange T, Larsen CF, Johansson PI, et al. Pilot randomized trial of fibrinogen in trauma Haemorrhage (PRooF-iTH): study protocol for a randomized controlled trial. Trials. 2016;17(1):1–8. · DOI
  92. Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-Centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017;4(6):e258–71. · doi:10.1016/s2352-3026(17)30077-7
  93. Hayakawa M, Gando S, Ono Y, Wada T, Yanagida Y, Sawamura A. Fibrinogen level deteriorates before other routine coagulation parameters and massive transfusion in the early phase of severe trauma: a retrospective observational study. Semin Thromb Hemost. 2015;41(1):35–42. · DOI
  94. Ziegler B, Bachler M, Haberfellner H, Innerhofer P, Hell T, Kaufmann M, et al. Efficacy of pre-Hospital administration of fibrinogen concentrate (Clottafact®) in trauma patients presumed to bleed (FIinTIC): Results from a multicentre double-blind, placebo-controlled, randomised, pilot trial. 2019. https://ssrn.com/abstract=3377525. Accessed 12 May 2019.
  95. Sharma V, Fan J, Jerath A, Pang K, Bojko B, Pawliszyn J, et al. Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass. Anaesthesia. 2012;67(11):1242–50. · doi:10.1111/j.1365-2044.2012.07266.x
  96. Moore EE, Moore HB, Gonzalez E, Sauaia A, Banerjee A, Silliman CC. Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient. Transfusion. 2016;56:S110–4. · DOI
  97. Godier A, Parmar K, Manandhar K, Hunt BJ. An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis. J Clin Pathol. 2017;70(2):154–61. · doi:10.1136/jclinpath-2016-203854
  98. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096–101. · DOI · Paper page
  99. Lipsky AM, Abramovich A, Nadler R, Feinstein U, Shaked G, Kreiss Y, et al. Tranexamic acid in the prehospital setting: Israel defense forces’ initial experience. Injury. 2014;45(1):66–70. · doi:10.1016/j.injury.2013.08.025
  100. Wright C. Battlefield administration of tranexamic acid by combat troops: a feasibility analysis. J R Army Med Corps. 2014;160(4):271–2. · doi:10.1136/jramc-2013-000152
  101. Aedo-Martín D, García-Cañas R, Navarro-Suay R, Martínez-Roldán M, Baños-Turza R, Tamburri-Bariain R. Use of tranexamic acid in combat casualties. Experience of the Spanish medical corps. Clinical series and literature review. Rev Esp Cir Ortop Traumatol. 2016;60(3):200–5.
  102. CRASH trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23–32. · DOI · Paper page
  103. Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, Akintan A, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16. · DOI · Paper page
  104. Roberts I. Fibrinolytic shutdown: fascinating theory but randomized controlled trial data are needed. Transfusion. 2016;56(Suppl 2):115–8. · doi:10.1111/trf.13490
  105. Jansen JA, Lameijer JRC, Snoeker BAM. Combined intravenous, topical and oral tranexamic acid administration in total knee replacement: evaluation of safety in patients with previous thromboembolism and effect on hemoglobin level and transfusion rate. Knee. 2017;24(5):1206–12. · doi:10.1016/j.knee.2017.07.004
  106. Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev. 2013;7:CD010562.
  107. Montroy J, Hutton B, Moodley P, Fergusson NA, Cheng W, Tinmouth A, et al. The efficacy and safety of topical tranexamic acid: a systematic review and meta-analysis. Transfus Med Rev. 2018;32(3):165–78. · DOI
  108. Picetti R, Shakur-Still H, Medcalf RL, Standing JF, Roberts I. What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood Coagul Fibrinolysis. 2019;30(1):1–10. · DOI · Paper page
  109. Schöchl H, Schlimp CJ, Maegele M. Tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate: data to support prehospital use? Shock. 2014;41:44–6. · doi:10.1097/shk.0000000000000093
  110. Boudreau RM, Deshpande KK, Day GM, Hinckley WR, Harger N, Pritts TA, et al. Prehospital tranexamic acid administration during aeromedical transport after injury. J Surg Res. 2019;233:132–8. · doi:10.1016/j.jss.2018.07.074
  111. Etchill EW, Myers SP, Raval JS, Hassoune A, SenGupta A, Neal MD. Platelet transfusion in critical care and surgery: evidence-based review of contemporary practice and future directions. Shock. 2017;47(5):537–49. · DOI
  112. Klein E, Farber S, Djerassi I, Toch R, Freeman G, Arnold P. The preparation and clinical administration of lyophilized platelet material to children with acute leukemia and aplastic anemia. J Pediatr. 1956;49(5):517–22. · doi:10.1016/s0022-3476(56)80138-8
  113. Stefanini M, Kistner SA. Platelets, platelet factors and platelet substitutes in the management of thrombocytopenic states. Bibl Haematol. 1958;7:378–81.
  114. Barroso J, Osborne B, Teramura G, Pellham E, Fitzpatrick M, Biehl R, et al. Safety evaluation of a lyophilized platelet-derived hemostatic product. Transfusion. 2018;58(12):2969–77. · DOI
  115. Inaba K, Barmparas G, Rhee P, Branco BC, Fitzpatrick M, Okoye OT, et al. Dried platelets in a swine model of liver injury. Shock. 2014;41(5):429–34. · doi:10.1097/shk.0000000000000141
  116. Burdette AJ, Andrew Pratt G III, Campagna MV, Sheppard FR. Evaluation of a new generation platelet-derived hemostatic agent in a rabbit thrombocytopenic model. Thromb Res. 2017;158:79–82. · DOI
  117. Chan V, Sarkari M, Sunderland R, St. John AE, White NJ, Kastrup CJ. Platelets loaded with liposome-encapsulated thrombin have increased coagulability. J Thromb Haemost. 2018;16(6):1226–35. · DOI
  118. Lashof-Sullivan M, Shoffstall A, Lavik E. Intravenous hemostats: challenges in translation to patients. Nanoscale. 2013;5(22):10719–28. · DOI
  119. Modery-Pawlowski CL, Tian LL, Ravikumar M, Wong TL, Gupta AS. In vitro and in vivo hemostatic capabilities of a functionally integrated platelet-mimetic liposomal nanoconstruct. Biomaterials. 2013;34(12):3031–41. · DOI
  120. Dyer MR, Hickman D, Luc N, Haldeman S, Loughran P, Pawlwoski C, et al. Intravenous administration of synthetic platelets (SynthoPlate™) in a mouse liver injury model of uncontrolled hemorrhage improves hemostasis. J Trauma Acute Care Surg. 2018;84(6):917–23. · doi:10.1097/ta.0000000000001893
  121. Lashof-Sullivan M, Holland M, Groynom R, Campbell D, Shoffstall A, Lavik E. Hemostatic nanoparticles improve survival following blunt trauma even after 1 week incubation at 50°C. ACS Biomater Sci Eng. 2016;2(3):385–92. · DOI
  122. Lashof-Sullivan MM, Shoffstall E, Atkins KT, Keane N, Bir C, VandeVord P, et al. Intravenously administered nanoparticles increase survival following blast trauma. Proc Natl Acad Sci U S A. 2014;111(28):10293–8. · DOI
  123. Onwukwe C, Maisha N, Holland M, Varley M, Groynom R, Hickman D, et al. Engineering intravenously administered nanoparticles to reduce infusion reaction and stop bleeding in a large animal model of trauma. Bioconjug Chem. 2018;29(7):2436–47. · DOI
  124. Welsch N, Brown AC, Barker TH, Lyon LA. Enhancing clot properties through fibrin-specific self-cross-linked PEG side-chain microgels. Colloids Surf B Biointerfaces. 2018;166:89–97. · DOI
  125. Chan LW, Wang X, Wei H, Pozzo LD, White NJ, Pun SH. A synthetic fibrin cross-linking polymer for modulating clot properties and inducing hemostasis. Sci Transl Med. 2015;7(277):277ra29. · DOI · Paper page
  126. Chan LW, Kim CH, Wang X, Pun SH, White NJ, Kim TH. PolySTAT-modified chitosan gauzes for improved hemostasis in external hemorrhage. Acta Biomater. 2016;31:178–85. · DOI · Paper page
  127. Chan KYT, Zhao C, Siren EMJ, Chan JCY, Boschman J, Kastrup CJ. Adhesion of blood clots can be enhanced when copolymerized with a macromer that is crosslinked by coagulation factor XIIIa. Biomacromolecules. 2016;17(6):2248–52. · DOI
  128. Morgan CE, Dombrowski AW, Rubert Pérez CM, Bahnson ESM, Tsihlis ND, Jiang W, et al. Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage. ACS Nano. 2015;10(1):899–909. · DOI
  129. Hansen CE, Myers DR, Baldwin WH, Sakurai Y, Meeks SL, Lyon LA, et al. Platelet–microcapsule hybrids leverage contractile force for targeted delivery of hemostatic agents. ACS Nano. 2017;11(6):5579–89. · DOI
  130. Behrens AM, Sikorski MJ, Kofinas P. Hemostatic strategies for traumatic and surgical bleeding. J Biomed Mater Res A. 2014;102(11):4182–94. · DOI · Paper page
  131. Grissom TE, Fang R. Topical hemostatic agents and dressings in the prehospital setting. Curr Opin Anesthesiol. 2015;28(2):210–6. · doi:10.1097/aco.0000000000000166
  132. Güven HE. Topical hemostatics for bleeding control in pre-hospital setting–then and now. Ulus Travma Acil Cerrahi Derg. 2017;23(5):357–61.
  133. Chiara O, Cimbanassi S, Bellanova G, Chiarugi M, Mingoli A, Olivero G, et al. A systematic review on the use of topical hemostats in trauma and emergency surgery. BMC Surg. 2018;18(1):68. · DOI · Paper page
  134. Khoshmohabat H, Paydar S, Kazemi HM, Dalfardi B. Overview of agents used for emergency hemostasis. Trauma Mon. 2016;21(1):e26023.
  135. Bennett BL, Littlejohn L. Review of new topical hemostatic dressings for combat casualty care. Mil Med. 2014;179(5):497–514. · DOI · Paper page
  136. Schauer SG, April MD, Naylor JF, Maddry JK, Arana AA, Dubick MA, et al. Prehospital application of hemostatic agents in Iraq and Afghanistan. Prehosp Emerg Care. 2018;22(5):1–10.
  137. Baylis JR, Yeon JH, Thomson MH, Kazerooni A, Wang X, St. John AE, et al. Self-propelled particles that transport cargo through flowing blood and halt hemorrhage. Sci Adv. 2015;1(9):e1500379. · DOI · Paper page
  138. Mueller GR, Pineda TJ, Xie HX, Teach JS, Barofsky AD, Schmid JR, et al. A novel sponge-based wound stasis dressing to treat lethal noncompressible hemorrhage. J Trauma Acute Care Surg. 2012;73(2):S134–9. · DOI
  139. Shina A, Lipsky AM, Nadler R, Levi M, Benov A, Ran Y, et al. Prehospital use of hemostatic dressings by the Israel Defence forces medical corps: a case series of 122 patients. J Trauma Acute Care Surg. 2015;79(4):S204–9. · doi:10.1097/ta.0000000000000720
  140. Leonard J, Zietlow J, Morris D, Berns K, Eyer S, Martinson K, et al. A multi-institutional study of hemostatic gauze and tourniquets in rural civilian trauma. J Trauma Acute Care Surg. 2016;81(3):441–4. · doi:10.1097/ta.0000000000001115
  141. Travers S, Lefort H, Ramdani E, Lemoine S, Jost D, Bignand M, et al. Hemostatic dressings in civil prehospital practice: 30 uses of QuikClot combat gauze. Eur J Emerg Med. 2016;23(5):391–4. · doi:10.1097/mej.0000000000000318
  142. Sena MJ, Douglas G, Gerlach T, Grayson JK, Pichakron KO, Zierold D. A pilot study of the use of kaolin-impregnated gauze (combat gauze) for packing high-grade hepatic injuries in a hypothermic coagulopathic swine model. J Surg Res. 2013;183(2):704–9. · doi:10.1016/j.jss.2013.02.039
  143. Schauer S, April M, Naylor J, Fisher A, Cunningham C, Ryan K, et al. QuikClot® combat gauze® use by ground forces in Afghanistan the prehospital trauma registry experience. J Spec Oper Med. 2017;17(2):101–6. · doi:10.55460/mjdi-7npa
  144. Choron RL, Hazelton JP, Hunter K, Capano-Wehrle L, Gaughan J, Chovanes J, et al. Intra-abdominal packing with laparotomy pads and QuikClot™ during damage control laparotomy: a safety analysis. Injury. 2017;48(1):158–64. · doi:10.1016/j.injury.2016.07.033
  145. Gegel BT, Austin PN, Johnson A. An evidence-based review of the use of a combat gauze (QuikClot) for hemorrhage control. AANA J. 2013;81(6):453–8.
  146. Cheng N, Cao X, Peng HT. Chitosan: a promising biomaterial for tissue engineering and hemorrhage control. In: Ferguson AN, O'Neill AG, editors. Focus on chitosan research. Hauppauge: USA Nova Science Publishers, Inc.; 2011. p. 49–82.
  147. Khan MA, Mujahid M. A review on recent advances in chitosan based composite for hemostatic dressings. Int J Biol Macromol. 2019;124:138–47. · DOI · Paper page
  148. Conley SP, Littlejohn LF, Henao J, DeVito SS, Zarow GJ. Control of junctional hemorrhage in a consensus swine model with hemostatic gauze products following minimal training. Mil Med. 2015;180(11):1189–95. · doi:10.7205/milmed-d-14-00541
  149. Pozza M, Millner RW. Celox (chitosan) for haemostasis in massive traumatic bleeding: experience in Afghanistan. Eur J Emerg Med. 2011;18(1):31–3. · doi:10.1097/mej.0b013e32833a5ee4
  150. Hatamabadi HR, Asayesh Zarchi F, Kariman H, Arhami Dolatabadi A, Tabatabaey A, Amini A. Celox-coated gauze for the treatment of civilian penetrating trauma: a randomized clinical trial. Trauma Mon. 2015;20(1):e23862. · DOI
  151. te Grotenhuis R, van Grunsven PM, Heutz WM, Tan EC. Prehospital use of hemostatic dressings in emergency medical services in the Netherlands: a prospective study of 66 cases. Injury. 2016;47(5):1007–11. · doi:10.1016/j.injury.2016.01.005
  152. Warriner Z, Lam L, Matsushima K, Benjamin E, Strumwasser A, Demetriades D, et al. Initial evaluation of the efficacy and safety of in-hospital expandable hemostatic minisponge use in penetrating trauma. J Trauma Acute Care Surg. 2019;86(3):424–30. · doi:10.1097/ta.0000000000002091
  153. Genyk Y, Kato T, Pomposelli JJ, Wright JK, Sher LS, Tetens V, et al. Fibrin sealant patch (TachoSil) vs oxidized regenerated cellulose patch (Surgicel original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg. 2016;222(3):261–8. · doi:10.1016/j.jamcollsurg.2015.12.007
  154. Erdogan D, Van Gulik TM. Evolution of fibrinogen-coated collagen patch for use as a topical hemostatic agent. J Biomed Mater Res B. 2008;85(1):272–8. · DOI
  155. Jackson M, Taher M, Burge J, Krishnamurti C, Reid T, Alving B. Hemostatic efficacy of a fibrin sealant dressing in an animal model of kidney injury. J Trauma. 1998;45:662–5. · doi:10.1097/00005373-199810000-00003
  156. Fischer CP, Bochicchio G, Shen J, Patel B, Batiller J, Hart JC. A prospective, randomized, controlled trial of the efficacy and safety of fibrin pad as an adjunct to control soft tissue bleeding during abdominal, retroperitoneal, pelvic, and thoracic surgery. J Am Coll Surg. 2013;217(3):385–93. · doi:10.1016/j.jamcollsurg.2013.02.036
  157. Koea JB, Batiller J, Patel B, Shen J, Hammond J, Hart J, et al. A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB. 2013;15(1):61–70. · doi:10.1111/j.1477-2574.2012.00583.x
  158. Pusateri AE, Kheirabadi BS, Delgado AV, Doyle JW, Kanellos J, Uscilowicz JM, et al. Structural design of the dry fibrin sealant dressing and its impact on the hemostatic efficacy of the product. J Biomed Mater Res B. 2004;70(1):114–21. · doi:10.1002/jbm.b.30031
  159. Kheirabadi BS, Acheson EM, Deguzman R, Crissey JM, Delgado AV, Estep SJ, et al. The potential utility of fibrin sealant dressing in repair of vascular injury in swine. J Trauma. 2007;62(1):94–103. · doi:10.1097/01.ta.0000251595.45451.d0
  160. Pusateri AE, Holcomb JB, Harris RA, MacPhee MJ, Charles NC, Beall LD, et al. Effect of fibrin bandage fibrinogen concentration on blood loss after grade V liver injury in swine. Mil Med. 2001;166(3):217–22. · doi:10.1093/milmed/166.3.217
  161. Holcomb J, MacPhee M, Hetz S, Harris R, Pusateri A, Hess J. Efficacy of a dry fibrin sealant dressing for hemorrhage control after ballistic injury. Arch Surg. 1998;133(1):32–5. · doi:10.1001/archsurg.133.1.32
  162. Jackson MR, Friedman SA, Carter AJ, Bayer V, Burge JR, MacPhee MJ, et al. Hemostatic efficacy of a fibrin sealant-based topical agent in a femoral artery injury model: a randomized, blinded, placebo-controlled study. J Vasc Surg. 1997;26(2):274–80. · doi:10.1016/s0741-5214(97)70189-7
  163. Baker JE, Goodman MD, Makley AT, Stevens-Topie SM, Veile RA, Mahoney EJ, et al. Evaluation of a novel fibrin sealant patch in hemorrhage control after vascular or hepatic injury. Mil Med. 2019;184(3/4):e290–6. · doi:10.1093/milmed/usy168
  164. Cheng CM, Meyer-Massetti C, Kayser SR. A review of three stand-alone topical thrombins for surgical hemostasis. Clin Ther. 2009;31(1):32–41. · doi:10.1016/j.clinthera.2009.01.005
  165. Izumi Y, Gika M, Shinya N, Miyabashira S, Imamura T, Nozaki C, et al. Hemostatic efficacy of a recombinant thrombin-coated polyglycolic acid sheet coupled with liquid fibrinogen, evaluated in a canine model of pulmonary arterial hemorrhage. J Trauma. 2007;63:783–7. · DOI
  166. Spotnitz W. Fibrin sealant patches: powerful and easy-to-use hemostats. Open Access Surg. 2014;4:71–9. · doi:10.2147/oas.s41516
  167. Navarro A, Brooks A. Use of local pro-coagulant haemostatic agents for intra-cavity control of haemorrhage after trauma. Eur J Trauma Emerg Surg. 2015;41(5):493–500. · doi:10.1007/s00068-014-0441-4
  168. Rickenbacher A, Breitenstein S, Lesurtel M, Frilling A. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery - a systematic review. Expert Opin Biol Ther. 2009;9(7):897–907. · DOI
  169. Watters JM, Van PY, Hamilton GJ, Sambasivan C, Differding JA, Schreiber MA. Advanced hemostatic dressings are not superior to gauze for care under fire scenarios. J Trauma. 2011;70(6):1413–8. · doi:10.1097/ta.0b013e318216b796
  170. Morrison JJ. Noncompressible torso hemorrhage. Crit Care Clin. 2017;33(1):37–54. · doi:10.1016/j.ccc.2016.09.001
  171. Lewis KM, Atlee H, Mannone A, Lin L, Goppelt A. Efficacy of hemostatic matrix and microporous polysaccharide hemospheres. J Surg Res. 2015;193(2):825–30. · doi:10.1016/j.jss.2014.08.026
  172. Tackett SM, Calcaterra D, Magee G, Lattouf OM. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28(6):1558–65. · doi:10.1053/j.jvca.2014.05.010
  173. Pursifull NF, Morris MS, Harris RA, Morey AF. Damage control management of experimental grade 5 renal injuries: further evaluation of FloSeal gelatin matrix. J Trauma. 2006;60:346–50. · doi:10.1097/01.ta.0000202514.96964.85
  174. Izzo F, Di Giacomo R, Falco P, Piccirillo M, Iodice R, Orlando AP, et al. Efficacy of a haemostatic matrix for the management of bleeding in patients undergoing liver resection: results from 237 cases. Curr Med Res Opin. 2008;24(4):1011–5. · doi:10.1185/030079908x280392
  175. Jameson M, Gross CW, Kountakis SE. FloSeal use in endoscopic sinus surgery: effect on postoperative bleeding and synechiae formation. Otolaryngol Head Neck Surg. 2006;27(2):86–90.
  176. Stacey MJ, Rampaul RS, Rengaragan A, Duffy JP, MacMillan RD. Use of FloSeal matrix hemostatic agent in partial splenectomy after penetrating trauma. J Trauma. 2008;64(2):507–8.
  177. Klemcke HG. Evaluation of FloSeal as a potential intracavitary hemostatic agent. J Trauma. 2006;60(2):385–9. · doi:10.1097/01.ta.0000204440.48338.79
  178. Su H, Wei S, Chen F, Cui R, Liu C. Tranexamic acid-loaded starch hemostatic microspheres. RSC Adv. 2019;9(11):6245–53. · DOI
  179. Gupta N, Chetter I, Hayes P, Albert HY, Moneta GL, Shenoy S, et al. Randomized trial of a dry-powder, fibrin sealant in vascular procedures. J Vasc Surg. 2015;62(5):1288–95. · doi:10.1016/j.jvs.2015.05.038
  180. Verhoef C, Singla N, Moneta G, Muir W, Rijken A, Lockstadt H, et al. Fibrocaps for surgical hemostasis: two randomized, controlled phase II trials. J Surg Res. 2015;194(2):679–87. · doi:10.1016/j.jss.2014.12.011
  181. Bochicchio GV, Gupta N, Porte RJ, Renkens KL, Pattyn P, Topal B, et al. The FINISH-3 trial: a phase 3, international, randomized, single-blind, controlled trial of topical Fibrocaps in intraoperative surgical hemostasis. J Am Coll Surg. 2015;220(1):70–81. · doi:10.1016/j.jamcollsurg.2014.09.019
  182. Kumar VA, Wickremasinghe NC, Shi S, Hartgerink JD. Nanofibrous snake venom hemostat. ACS Biomater Sci Eng. 2015;1(12):1300–5. · DOI
  183. Ruan L, Zhang H, Luo H, Liu J, Tang F, Shi Y-K, et al. Designed amphiphilic peptide forms stable nanoweb, slowly releases encapsulated hydrophobic drug, and accelerates animal hemostasis. Proc Natl Acad Sci U S A. 2009;106(13):5105–10. · DOI
  184. Ellis-Behnke RG, Liang Y-X, Tay DKC, Kau PWF, Schneider GE, Zhang S, et al. Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine. 2006;2(4):207–15. · DOI · Paper page
  185. Hsu BB, Conway W, Tschabrunn CM, Mehta M, Perez-Cuevas MB, Zhang S, et al. Clotting mimicry from robust hemostatic bandages based on self-assembling peptides. ACS Nano. 2015;9(9):9394–406. · DOI
  186. Zhao X, Guo B, Wu H, Liang Y, Ma PX. Injectable antibacterial conductive nanocomposite cryogels with rapid shape recovery for noncompressible hemorrhage and wound healing. Nat Commun. 2018;9(1):2784. · DOI · Paper page
  187. Rago AP, Sharma U, Duggan M, King DR. Percutaneous damage control with self-expanding foam: pre-hospital rescue from abdominal exsanguination. Trauma. 2016;18(2):85–91. · doi:10.1177/1460408615617790
  188. Peev MP, Rago A, Hwabejire JO, Duggan MJ, Beagle J, Marini J, et al. Self-expanding foam for prehospital treatment of severe intra-abdominal hemorrhage: dose finding study. J Trauma Acute Care Surg. 2014;76(3):619–24. · DOI
  189. Duggan MJ, Mejaddam AY, Beagle J, deMoya MA, Velmahosa GC, Alam HB, et al. Development of a lethal, closed-abdomen grade V hepato-portal injury model in non-coagulopathic swine. J Surg Res. 2013;182(1):101–7. · doi:10.1016/j.jss.2012.07.048
  190. Mesar T, Martin D, Lawless R, Podbielski J, Cook M, Underwood S, et al. Human dose confirmation for self-expanding intra-abdominal foam: a translational, adaptive, multicenter trial in recently deceased human subjects. J Trauma Acute Care Surg. 2015;79(1):39–47. · doi:10.1097/ta.0000000000000696
  191. Falus G. Tissue sealant for use in non-compressible hemorrhage. US Patent. 2012;8:314,211.
  192. Filips D, Logsetty S, Tan J, Atkinson I, Mottet K. The iTClamp controls junctional bleeding in a lethal swine exsanguination model. Prehosp Emerg Care. 2013;17(4):526–32. · doi:10.3109/10903127.2013.818177
  193. Walchak A, Zarow G, McLean J, Stuart SM, Roszko P. Pilot study of a novel swine model for controlling junctional hemorrhage using the iTClamp in conjunction with hemostatic agents. Mil Med. 2019;184(Suppl 1):367–73.
  194. Morrison JJ, Galgon RE, Jansen JO, Cannon JW, Rasmussen TE, Eliason JL. A systematic review of the use of resuscitative endovascular balloon occlusion of the aorta in the management of hemorrhagic shock. J Trauma Acute Care Surg. 2016;80(2):324–34. · doi:10.1097/ta.0000000000000913
  195. Inoue J, Shiraishi A, Yoshiyuki A, Haruta K, Matsui H, Otomo Y. Resuscitative endovascular balloon occlusion of the aorta might be dangerous in patients with severe torso trauma: a propensity score analysis. J Trauma Acute Care Surg. 2016;80(4):559–67. · DOI
  196. Campion EM, Fox CJ. Prehospital hemorrhage control and REBOA. Curr Trauma Rep. 2019;5(3):129–36. · DOI
  197. Drew B, Bennett BL, Littlejohn L. Application of current hemorrhage control techniques for backcountry care: part one, tourniquets and hemorrhage control adjuncts. Wilderness Environ Med. 2015;26(2):236–45. · doi:10.1016/j.wem.2014.08.016
  198. Jensen NHL, Stensballe J, Afshari A. Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review. Acta Anaesthesiol Scand. 2016;60(8):1033–42. · DOI
  199. Akbari E, Safari S, Hatamabadi H. The effect of fibrinogen concentrate and fresh frozen plasma on the outcome of patients with acute traumatic coagulopathy: a quasi-experimental study. Am J Emerg Med. 2018;36(11):1947–50. · doi:10.1016/j.ajem.2018.02.018
  200. Zhang Y-J, Gao B, Liu X-W. Topical and effective hemostatic medicines in the battlefield. Int J Clin Exp Med. 2015;8(1):10–9.

200 of 222 shown

Cited by

See all 81

Metadata

Authors
Peng, H. T.
Venue
Military Medical Research
Publisher
Elsevier BV
Published
2020-03-25
Volume
7
Issue
1
ISSN
2054-9369
Cited by
81
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hemostatic agents for prehospital hemorrhage control: a narrative review. https://app.cochat.ai/papers/10.1186/s40779-020-00241-z
The paper
Peng, H. T. (2020). Hemostatic agents for prehospital hemorrhage control: a narrative review. Military Medical Research. https://doi.org/10.1186/s40779-020-00241-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.